Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CEL-SCI Corp

Healthcare US CVM

1.49USD
0.00(0%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.471.53
LowHigh

52 Week Range

1.9813.48
LowHigh

Fundamentals

  • Previous Close 1.49
  • Market Cap32.22M
  • Volume141311
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.23074M
  • Revenue TTM0.03M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -15.13414M
  • Diluted EPS TTM-3.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -25.41106M -26.92047M -32.19430M -36.70068M -36.36111M
Minority interest - - - - -
Net income -25.41106M -26.92047M -32.36586M -38.26769M -39.18756M
Selling general administrative 8.92M 7.79M 9.00M 10.71M 13.09M
Selling and marketing expenses - - - - -
Gross profit -3.88515M -3.96918M -3.95833M - -
Reconciled depreciation 3.89M 3.97M 3.96M 3.83M 2.23M
Ebit -24.76212M -26.17479M -31.51888M -36.06279M -36.19413M
Ebitda -20.87696M -22.20561M -27.56055M -32.15752M -32.28585M
Depreciation and amortization 3.89M 3.97M 3.96M 3.91M 3.91M
Non operating income net other - - - 0.44M 0.98M
Operating income -24.80974M -26.35247M -31.47607M -36.06279M -36.19413M
Other operating expenses 24.81M 26.35M 31.48M 36.06M 36.19M
Interest expense 0.65M 0.75M 0.68M 1.08M 1.15M
Tax provision - - - - -
Interest income - - 0.68M 0.71M 1.84M
Net interest income -0.64894M -0.74567M -0.67542M -1.08103M -1.14929M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.63M 1.57M 2.83M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 20.92M 22.38M 31.48M 36.06M 36.19M
Cost of revenue 3.89M 3.97M 3.96M - -
Total other income expense net -0.60132M -0.56799M -0.71823M -0.63789M -0.16698M
Discontinued operations - - - - -
Net income from continuing ops -25.41106M -26.92047M -32.19430M -36.70068M -36.36111M
Net income applicable to common shares - - -32.36586M -37.62980M -36.71197M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 28.16M 26.99M 30.53M 50.52M 75.87M
Intangible assets 0.12M 0.17M 0.20M 0.21M 0.28M
Earning assets - - - - -
Other current assets 0.34M 0.30M - 2.76M 1.00M
Total liab 12.20M 14.12M 17.31M 18.36M 19.34M
Total stockholder equity 15.96M 12.87M 13.21M 32.16M 56.53M
Deferred long term liab - - - - -
Other current liab 1.63M 0.93M 1.61M 1.31M 0.44M
Common stock 0.08M 0.64M 0.47M 0.43M 0.43M
Capital stock 0.08M 0.64M 0.47M 0.43M 0.43M
Retained earnings -539.42292M -514.01186M -487.09140M -454.89709M -418.19641M
Other liab - - - 0.12M 0.12M
Good will - - - - -
Other assets 3.54M 3.79M - 0.16M 1.91M
Cash 10.95M 4.74M 4.15M 22.67M 36.06M
Cash and equivalents 10.95M 4.74M - 22.67M 36.06M
Total current liabilities 5.13M 4.62M 5.59M 4.66M 3.94M
Current deferred revenue - - - - 1.13M
Net debt -1.56956M 6.88M 9.43M -7.36891M -20.08781M
Short term debt 2.44M 2.24M 1.97M 1.73M 0.70M
Short long term debt - - - - -
Short long term debt total 9.38M 11.62M 13.57M 15.30M 15.97M
Other stockholder equity 555.30M 526.24M 499.83M 486.63M 474.30M
Property plant equipment 12.90M 16.98M - 12.05M 13.66M
Total current assets 11.60M 6.06M 6.92M 25.44M 45.27M
Long term investments - - - - -
Net tangible assets - - - 31.95M 56.26M
Short term investments 0.00709M 0.00350M - 0.00000M 6.15M
Net receivables - - - -2.00171M 0.05M
Long term debt - - - - -
Inventory 0.30M 1.02M 2.25M 2.00M 2.01M
Accounts payable 1.06M 1.45M 2.01M 1.62M 1.68M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.43M 0.43M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -454.89709M -418.19641M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -12885.82124M 3.79M 2.39M 0.16M 1.91M
Deferred long term asset charges - - - - -
Non current assets total 16.56M 20.94M 23.61M 25.09M 30.60M
Capital lease obligations 9.38M 11.62M 13.57M 15.30M 15.97M
Long term debt total 5.68M 7.96M - 11.72M 13.25M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -0.10809M -0.37226M 6.15M -6.14576M
Change to liabilities - - - 0.56M 0.84M
Total cashflows from investing activities -38.10900M -0.10809M - 5.49M -15.18473M
Net borrowings -2.01118M -1.77338M - -1.38650M -1.07939M
Total cash from financing activities 23373.13M 19.51M 4.69M -0.63843M 54.52M
Change to operating activities - - - 2.27M 0.26M
Net income -25411.05500M -26.92047M -32.19430M -36.70068M -36.36111M
Change in cash 6215.29M 0.59M -18.52640M -13.38801M 20.55M
Begin period cash flow 4738.17M 4.15M 22.67M 36.06M 15.51M
End period cash flow 10953.46M 4.74M 4.15M 22.67M 36.06M
Total cash from operating activities -17119.73700M -18.81121M -22.84856M -18.24095M -18.78702M
Issuance of capital stock 28.51M 23.66M 6.55M 0.00000M 47.36M
Depreciation 3885.15M 3.97M 3.96M 3.83M 2.23M
Other cashflows from investing activities 0.00000M -0.01321M - -0.02274M -6.16840M
Dividends paid - - - - -
Change to inventory 0.97M -0.17261M -0.15673M -0.15943M -1.18653M
Change to account receivables - - 0.44M 0.05M 0.50M
Sale purchase of stock 28.51M 23.66M - 0.13M 53.99M
Other cashflows from financing activities 23349.98M -2.37051M -0.29762M 0.75M 8.24M
Change to netincome - - - 11.84M 14.91M
Capital expenditures 38.11M 0.09M 0.37M 0.66M 9.04M
Change receivables - - - 0.05M -
Cash flows other operating - - - 2.30M -0.40987M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -13.38801M 20.55M
Change in working capital 1.16M -1.21219M -1.77745M 2.54M -0.48347M
Stock based compensation 1911.00M 4.27M 7.15M 11.61M 13.89M
Other non cash items 2494.01M 1.08M 0.02M 0.48M 1.23M
Free cash flow -17157.84600M -18.90608M -23.22082M -18.90158M -27.82599M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CVM
CEL-SCI Corp		 - -% 1.49 - 23.04 92.88 2.89 88.93 11.00
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

CEL-SCI Corp

8229 Boone Boulevard, Vienna, VA, United States, 22182

Key Executives

Name Title Year Born
Mr. Geert R. Kersten Esq. Chief Exec. & Financial Officer, Treasurer and Director 1959
Ms. Patricia B. Prichep Sr. VP of Operations & Corp. Sec. 1951
Dr. Eyal Talor Ph.D. Chief Scientific Officer 1956
Dr. Daniel H. Zimmerman Ph.D. Sr. VP of Research & Cellular Immunology 1941
Mr. John Cipriano Sr. VP of Regulatory Affairs 1942
Ms. Patricia B. Prichep Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary 1951
Mr. John Cipriano Senior Vice President of Regulatory Affairs 1942
Dr. Giovanni Selvaggi M.D. Acting Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions